|
Nephritis
|
0.310 |
Therapeutic
|
disease |
CTD_human |
Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats.
|
11044214 |
2000 |
|
Nephritis
|
0.310 |
Biomarker
|
disease |
BEFREE |
The results of the current investigation provide a potential new strategy in which antagonism of Gal-9 may be beneficial for the treatment of nephritis and arthritis in patients with SLE through targeting of activated macrophages.
|
29481735 |
2018 |
|
Meningitis, Pneumococcal
|
0.200 |
Biomarker
|
disease |
RGD |
Gene and protein expression of galectin-3 and galectin-9 in experimental pneumococcal meningitis.
|
17706429 |
2007 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In stratified analyses, high Gal-9 expression was significantly correlated with improved OS in hepatocellular carcinoma and colon cancer and with improved DFS/RFS in gastric cancer and non-small cell lung cancer.
|
29765332 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum galectin-9 concentration represents a potential biomarker of liver fibrosis in patients with chronic liver diseases, regardless of chronic inflammation or the presence of HCC complications.
|
28618039 |
2018 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using flow cytometry we analysed expression of checkpoint molecules (PD-1, PD-L1, CTLA-4, GITR, Tim-3) on peripheral CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs and their secretion of inhibitory mediators (IL-10, IL-35, TGF-beta, galectin-9) in 116 individuals (50 patients with HCC, 41 non-tumour bearing liver disease controls, 25 healthy controls).
|
31724091 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunofluorescence staining revealed a colocalization of Tim-3(+) T cells and galectin-9(+) KCs in HCC.
|
22505239 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In fact, circulating levels of PD-L1 and Galectin-9 were predictive of HCC-specific survival independently of intra-tumoral levels and baseline clinicopathologic characteristics.
|
31337865 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that galectin-9 might be a new prognostic factor with antimetastatic potential in patients with hepatocellular carcinoma.
|
22938412 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The dichotomous nature of Gal-9 is evident in hepatocellular carcinoma, where loss of expression in hepatocytes promotes tumor growth and metastasis, whereas overexpression by Kupffer cells and endothelial cells inhibits the antitumor immune response.
|
28195343 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gal-9 was reported to have anti-metastatic activity in patients with malignant melanoma, breast cancer, and hepatocellular carcinoma.
|
28492371 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that low expression levels of PD-L1 and Gal-9 in combination with low CD8<sup>+</sup>TIL count predict extremely poor HCC-specific survival and it requires a change in two of these parameters to significantly improve prognosis.
|
28344887 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To summarize the results, galectin-9 inhibited the growth of the HCC cell lines HLE and Li-7 in vitro and Li-7 in vivo inducing apoptosis.
|
25823465 |
2015 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IFN-γ induces up-regulation of galectin-9 and EZH2 in HCC cell lines.
|
29316949 |
2018 |
|
Rheumatoid Arthritis
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Galectin-9 serum levels were significantly increased in RA patients compared to the control group (p<0.0001).
|
31600237 |
2019 |
|
Rheumatoid Arthritis
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
The Gal-9 expressions in the cytoplasm of CD4+ T, CD8+ T, Treg, and DNT cells positively correlated with plasma TNF-α levels in RA patients.
|
31820713 |
2019 |
|
Rheumatoid Arthritis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Correspondingly, treatment with Gal-9 triggered citrullination of intracellular granulocyte proteins that are known contributors to RA pathogenesis (i.e., myeloperoxidase, alpha-enolase, MMP-9, lactoferrin).
|
31430907 |
2019 |
|
Rheumatoid Arthritis
|
0.060 |
Biomarker
|
disease |
BEFREE |
We conclude that, unlike exogenous Gal9, endogenous Gal9 is protective against apoptosis and enhances synovial fibroblast viability suggesting that its role in RA is both pathogenic and pro-inflammatory.
|
30150656 |
2018 |
|
Rheumatoid Arthritis
|
0.060 |
Biomarker
|
disease |
LHGDN |
To compare the expression of galectin 9 (Gal-9) in synovial tissue (ST) from rheumatoid arthritis (RA) patients and osteoarthritis (OA) patients and to evaluate the effects of Gal-9 on fibroblast-like synoviocytes (FLS) in these patients.
|
18050192 |
2007 |
|
Rheumatoid Arthritis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Gal-9-mediated apoptosis of CD4+ T cells is dysfunctional in RA patients.
|
21717191 |
2012 |
|
melanoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Gal-9 was reported to have anti-metastatic activity in patients with malignant melanoma, breast cancer, and hepatocellular carcinoma.
|
28492371 |
2017 |
|
melanoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The CCR7<sup>+</sup> melanoma cell subpopulation coexpressed PD-L1 and Galectin-9 and had stemness properties.
|
30940644 |
2019 |
|
melanoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Inappropriate production of gal-9 has been reported in several human malignancies and viral diseases like nasopharyngeal, pancreatic and renal carcinomas, metastatic melanomas and chronic active viral hepatitis.
|
30204750 |
2018 |
|
melanoma
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
This study aimed to investigate the association of TIM-3 and LGALS9 DNA methylation with gene expression, patients' survival, as well as molecular and immune correlates in malignant melanoma.
|
31747929 |
2019 |
|
melanoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Lastly, there was a positive correlation between increasing numbers of CD206 macrophages and galectin-9 expression in tumors, and high levels of CD206 macrophages correlated negatively with melanoma survival.
|
29732570 |
2018 |